ReviewFrontiers in child and adolescent psychiatry2026
Genetic variability and response to sertraline in pediatric populations: a review on pharmacogenetics, pharmacokinetics, and the risk of adverse events.
Review in Frontiers in child and adolescent psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anxiety disorders in the pediatric population represent a highly prevalent mental health concern whose pharmacological management has been consolidated through the use of selective serotonin reuptake inhibitors (SSRIs). Among these agents, sertraline is one of the most frequently prescribed; however, its efficacy and safety in children and adolescents exhibit substantial interindividual variability, largely attributed to clinical, physiological, and genetic factors. This review aimed to analyze the current evidence on the efficacy, safety, and optimization strategies for sertraline therapy in pediatric patients, with a particular focus on pharmacokinetic and pharmacogenetic determinants that modulate therapeutic response. Available evidence indicates that genetic variants in CYP2C19, CYP2D6, and ABCB1 significantly influence hepatic metabolism, plasma exposure, and drug tolerability. These differences support the integration of pharmacogenetic testing as a clinical tool to individualize dosing and prevent adverse effects. In addition, population pharmacokinetic modeling has emerged as a valuable approach to design personalized therapeutic regimens, especially for patients with medical comorbidities or atypical metabolic profiles. In conclusion, the integration of clinical, genetic, and pharmacokinetic information into pediatric psychiatric practice may facilitate the advancement of precision medicine, promoting safer, more effective, and individualized sertraline-based treatments for anxiety disorders in children and adolescents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.